Johnson & Johnson (SNSE:JNJ)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 598.54T +53.8% |
| Revenue (ttm) | 90.34T +8.1% |
| Net Income | 19.41T -7.2% |
| EPS | 7,958.72 -7.6% |
| Shares Out | n/a |
| PE Ratio | 30.84 |
| Forward PE | n/a |
| Dividend | 4,966.63 (2.00%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 265.95 |
| Day's Range | n/a |
| 52-Week Range | 156.65 - 265.95 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review
Johnson & Johnson announced that the FDA has granted Priority Review to the supplemental Biologics License Application for Rybrevant Faspro, or subcutaneous amivantamab and hyaluronidase-lpuj for adul...
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients...
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary...
Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36
The company states: “The combination of these two transactions is also expected to reduce the Company’s 2027 Adjusted Operational EPS and Adjusted EPS by approximately $1.36, consisting of approximate...
Johnson & Johnson lowers 2026 profit forecast
Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedici...
Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68
Prior guidance was $11.50-$11.65. On July 29, 2026, Johnson & Johnson announced the completion of the acquisition of Firefly Bio, Inc. and the entry into strategic agreements and collaboration with…
Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B
Cuts FY26 operating margin view to down 75bps from up 75bps vs. prior year.
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CA...
Explainer: Can J&J finally put the talc litigation behind it?
After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that cou...
Johnson & Johnson price target raised to $300 from $290 at Argus
Argus analyst David Toung raised the firm’s price target on Johnson & Johnson to $300 from $290 and keeps a Buy rating on the shares. The firm is citing the…
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits
Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
J&J Strikes $5.5B Talc Settlement after Years of Lawsuits; JNJ Stock Rises
Johnson & Johnson ($JNJ) shares rose 1.52% in after-hours trading on Monday after the company announced a $5.5 billion settlement to resolve tens of thousands of lawsuits. The lawsuits claimed…
Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit
Landmark deal covers about 76,000 claims and could end contentious, decade-long legal battle
J&J offers $5.5bn to settle baby powder lawsuits
Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer.
Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits
The drugmaker aims to put an end to litigation that has been going on for more than a decade.
Johnson & Johnson announces $5.5 billion settlement of talc lawsuits
Johnson & Johnson said on Monday it has reached a $5.5 billion settlement that will resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer.
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation wit...
Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios
Robert Kiyosaki's warning that the world faces what he called the “greatest depression in world history” does not seem to be a Wall Street consensus forecast. Yet, the Rich Dad Poor Dad author and a l...
Johnson & Johnson’s multiple myeloma therapy shows efficacy in Phase 3 trial
Johnson & Johnson announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating Tecvayli – teclistamab-cqyv – + Talvey – talquetamab-tgvs -, a BCMA and GP...
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluat...
US judge casts doubt on 69,000 cases alleging J&J talc caused cancer
A federal judge cast doubt on Wednesday on claims by approximately 69,000 people alleging that Johnson & Johnson's baby powder and other talc products caused ovarian cancer, saying plaintiffs must pr...
Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon
Shares in medical group Johnson & Johnson ($JNJ) were healthier today after it received the green light to begin the “next era” of robotic surgery. Robotic Operating Tables The company…
Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved
The approval opens a new market for the healthcare company.